MedBulletinsAura Celeste
Orthopedics

Monthly orthopedics and trauma bulletin — October 5, 2026

🎧 Listen to this issueAudio newscast · 4:31 min

Period covered: September 5 to October 5, 2026. A light month for large trials: we include 8 verified items rather than padding. In arthroplasty, the only high-impact finding was the UK registry analysis of robotic surgery; there were no verifiable periprosthetic joint infection studies from this period. Outside North America and Western Europe there were two verifiable items (Australia and Taiwan); in Latin America and the Caribbean there were no verifiable clinical publications from the period, only society meeting announcements.

Arthroplasty and reconstructive surgery

1. Robotic hip and knee arthroplasty does not reduce overall revision risk

[Publication] [United Kingdom]
Two National Joint Registry analyses published in The BMJ on September 30 using target trial emulation: 666,283 hip arthroplasties (10,203 robotic) and 697,145 knee arthroplasties (22,111 robotic) performed between 2018 and 2024, with a mean follow-up of 2.5 years. There were no differences in implant survival, all-cause or cause-specific revision, or intraoperative complications. The one exception: a lower risk of revision for malposition in robotic hips.
Why it matters: this is the largest registry evidence to date, arriving as robots cost about £1 million plus £1,000–2,500 per case; it is observational, short-term and lacks functional outcomes, but for Dominican hospitals considering a robot purchase, the "fewer revisions" argument does not hold in the short term.
https://doi.org/10.1136/bmj-2026-100709
https://doi.org/10.1136/bmj-2026-100691
https://www.qmul.ac.uk/news/latest-news/2026/medicine-and-dentistry/fmd/robotic-hip-and-knee-surgery-fails-to-cut-overall-risk-of-repeat-surgery.html

Trauma and fractures

2. Surgical delay in hip fracture: no signal at 3 months, a signal at 1 year

[Publication] [Norway]
Single-center cohort with prospectively collected data (European Journal of Trauma and Emergency Surgery, online September 23): 4,136 hip fractures from 2015 to 2023. At 3 months (primary endpoint), mortality was numerically higher with delays beyond 12 hours, without statistical significance. At 1 year, waiting 12–24 hours was associated with an adjusted OR of 1.38, and more than 48 hours with 1.80.
Why it matters: it supports early surgery, but the authors themselves urge caution: it is observational, the signal appears only in the most confounding-prone endpoint, and it contrasts with the HIP ATTACK trial; in settings where delay stems from lack of operating room time or implants, the organizational message still holds.
https://link.springer.com/article/10.1007/s00068-026-03351-w

Spine, shoulder, sports medicine and arthroscopy

3. Supervised exercise for persistent symptoms after ACL reconstruction

[Clinical trial] [Australia]
La Trobe University randomized trial published in Annals of Internal Medicine on September 29: 184 adults aged 18 to 40 with persistent knee problems 1 to 3 years after anterior cruciate ligament reconstruction. Four months of progressive physiotherapist-supervised exercise, compared with a single education session, improved symptoms and muscle strength without cartilage deterioration.
Why it matters: it supports prescribing structured late rehabilitation for patients who "never quite recover"; follow-up is short and it does not yet show prevention of early osteoarthritis, which affects about half of these patients within 10 years.
https://www.acpjournals.org/doi/10.7326/ANNALS-26-02460

4. Synergy cervical disc vs. discectomy and fusion at 2 years

[Industry] [United States]
The manufacturer presented at the Society for Minimally Invasive Spine Surgery annual forum (press release September 16) data from its multicenter IDE study: 175 disc patients vs. 192 propensity-matched historical ACDF controls. Composite clinical success at 24 months: 87.1% vs. 56.6% (p<0.0001); mean neck pain 15.6 vs. 30.2 out of 100.
Why it matters: the control group is historical, not randomized, and the data come from the company; useful device information, not proof of superiority.
https://orthospinenews.com/2026/09/17/synergy-spine-solutions-highlights-superior-two-year-clinical-outcomes-for-fda-approved-synergy-disc-at-society-for-minimally-invasive-spine-surgery/

Osteoporosis, rehabilitation and pediatric orthopedics

5. The osteoporosis treatment gap depends on the type of surgery, not on bone density

[Publication] [Taiwan]
Retrospective tertiary-center cohort (Journal of Clinical Medicine, October 4): 6,171 operations in 5,739 patients from 2015 to 2025. Within 1 year, osteoporosis treatment was started in 46.9% after vertebroplasty, 43.1% after hip fracture fixation, 33.0% after hip arthroplasty, 17.4% after lumbar fusion and 7.2% after total knee arthroplasty. The gap persisted among 871 operations (829 patients) with T ≤ −2.5 (48.2% vs. 7.5%); among untreated patients aged 50 or older, each one-unit lower T-score was associated with a major osteoporotic fracture HR of 1.25.
Why it matters: although shaped by Taiwan's reimbursement rules, it reflects a universal problem: the osteoporotic elective patient leaves the operating room untreated; a fracture liaison service or a preoperative bone health protocol is applicable in the Dominican Republic.
https://www.mdpi.com/2077-0383/15/19/7683

6. microRNA test predicting scoliosis progression receives FDA Breakthrough Device designation

[Regulatory FDA] [United States]
On September 29, VB Spine announced Breakthrough Device designation for ScolimiR-3D, a blood test using a six-microRNA panel to classify progression risk in adolescent idiopathic scoliosis. The underlying study, in Scientific Reports, included 116 patients and reported 100% sensitivity and specificity in an internal hold-out test set (20% of cases, held back from training).
Why it matters: designation is not approval; perfect figures in a small sample require independent external validation before they influence bracing or surgical decisions.
https://biospace.com/press-releases/vb-spine-announces-fda-breakthrough-device-designation-for-new-blood-test-designed-to-identify-patients-at-risk-for-scoliosis-progression
https://secure.businesswire.com/news/home/20260929164733/en/VB-Spine-Announces-FDA-Breakthrough-Device-Designation-for-New-Blood-Test-Designed-to-Identify-Patients-at-Risk-for-Scoliosis-Progression

Cross-cutting

7. DePuy Synthes unveils plates, a remotely monitored fixator and AI guidance at OTA 2026

[Industry] [United States]
At the Orthopaedic Trauma Association annual meeting (Nashville, September 23–26; announcement dated September 23), the company showed four VOLT plating systems built on CT-derived anatomical data, the Bluetooth-enabled MAXFRAME AUTOSTRUT fixator (already marketed in the U.S.) and VELY, a tracker-free AI-assisted intraoperative 3D guidance system expected in 2027.
Why it matters: the announcement includes no clinical data or regulatory clearance dates; this is market information, not evidence.
https://www.news-medical.net/news/20260923/DePuy-Synthes-showcases-next-generation-trauma-innovations-at-OTA-2026.aspx

8. Ireland proposes a commission of investigation into pediatric scoliosis and hip dysplasia care

[Health policy] [Ireland]
On September 28 the scoping report was published recommending a commission of investigation, largely in private, into scoliosis, spina bifida and hip dysplasia care at Children's Health Ireland from 2019 to 2025, including spinal surgery waiting lists. Family advocacy groups object to the format and start date.
Why it matters: not a clinical guideline but a health policy decision; a reminder that delays in pediatric spine surgery are a patient safety issue, including in systems with waiting lists like ours.
https://irishtimes.com/opinion/editorials/2026/09/28/the-irish-times-view-on-the-scoliosis-inquiry-families-must-be-heard

Upcoming meetings and dates

Curated by Aura Celeste · Medical Bulletins

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.